Rituximab, Pembrolizumab, and Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 37
Summary
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Refractory Diffuse Large B Cell Lymphoma
- Refractory Follicular Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
OUTLINE: INDUCTION: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive rituximab or obinutuzumab IV on days 1, 8, and 15 of cycle 1 and on day 1 of cycle 2. Cycles repeat every 3 weeks for 4 cycles in the absence of disease progression or unacceptable t...
OUTLINE: INDUCTION: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive rituximab or obinutuzumab IV on days 1, 8, and 15 of cycle 1 and on day 1 of cycle 2. Cycles repeat every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab Iv on day 1 of cycles 5, 9, 13, 17, 21, and 25 only. After completion of study treatment, patients are followed up for 90 days.
Tracking Information
- NCT #
- NCT03401853
- Collaborators
- National Cancer Institute (NCI)
- Merck Sharp & Dohme Corp.
- Investigators
- Principal Investigator: Stephen D. Smith Fred Hutch/University of Washington Cancer Consortium
Get Well Soon